Look back at pharma news in the week to July 17, 2020

19 July 2020

By Barbara Obstoj-Cardwell. Editor

Last week’s notable research news included disappointing results for Swiss pharma giant Roche’s Tecentriq in combination with Avastin in the treatment of ovarian cancer, and US firm Moderna posted promising results for its COVID-19 vaccine candidate mRNA-1273, but questions were raised about the length of protection it provided. Roche was also in the news for its collaboration with Blueprint Medicines on the development of the US biotech’s targeted cancer candidate pralsetinib. Elsewhere, India’s Biocon received approval from the domestic regulator, the DCGI, to market its Alzumab to treat respiratory complications in COVID-19 patients.

Tecentriq’s ovarian failure highlights a changing market

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK